NextFin news, on November 5, 2025, researchers from the Icahn School of Medicine at Mount Sinai, in collaboration with the Max Planck Institute for Biology of Ageing in Cologne, Germany, The Rockefeller University, The City University of New York, and other global partners, announced the identification of a distinct neuroprotective microglia subtype with potential as an immunotherapy target for Alzheimer’s disease (AD). The findings, published in Nature, reveal that microglia with reduced expression of the transcription factor PU.1 and co-expression of the lymphoid-like receptor CD28 play a critical role in limiting neuroinflammation and curbing the hallmark pathological features of AD, including amyloid plaque accumulation and tau protein spreading within the brain.
The team employed advanced methodologies involving AD mouse models, human brain tissue, and cell cultures to demonstrate that downregulation of PU.1 encourages the expression of lymphoid immunoregulatory receptors on microglia. Despite their small numbers, these microglia exert a widespread suppressive effect on neuroinflammation, thereby protecting cognitive functions and promoting survival in preclinical models. Importantly, experimental deletion of CD28 on these cells resulted in heightened inflammation and accelerated plaque progression, underscoring the receptor's pivotal role in mediating this protective phenotype.
PU.1, a master transcription factor encoded by the gene SPI1, regulates gene expression in myeloid cells, including microglia. Prior genomic research by senior co-author Alison Goate linked variants in SPI1 with reduced Alzheimer’s risk, providing genetic validation for the observed mechanistic protective pathway. CD28, traditionally understood as a co-stimulatory molecule in T cell activation, was found here to also regulate microglial immune functions, adding a novel dimension to the immunological understanding of AD. This discovery aligns with burgeoning evidence regarding the shared regulatory frameworks of immune cells, bridging innate and adaptive immunity within the central nervous system.
Dr. Anne Schaefer, senior author and Director of the Max Planck Institute for Biology of Ageing, emphasized that microglia are not unidirectional agents of neurodegeneration but display remarkable functional plasticity, capable of switching to protective states that slow disease progression. The collaboration highlights how integrative international research combining genetics, immunology, and neurobiology can yield breakthroughs with clinical translation potential.
This foundational work offers a framework to develop microglia-targeted immunotherapies aimed at reprogramming neuroinflammatory responses in Alzheimer’s disease. Given the global projected increase in AD prevalence—expected to surpass 20 million cases in the United States alone within the next two decades—the therapeutic imperative is acute. Immune modulation strategies leveraging the PU.1-CD28 axis could complement or surpass current amyloid-targeting therapies, which have faced challenges in efficacy and safety.
From a biomedical innovation perspective, this discovery opens avenues for drug development targeting transcriptional and receptor-mediated pathways in microglia. Early-stage therapeutic modalities could include small molecule inhibitors or gene therapy approaches to modulate PU.1 expression, as well as development of biologics to enhance CD28-mediated microglial immunoregulatory functions. Additionally, identification of biomarkers linked to this protective microglial signature might improve early diagnosis and patient stratification for personalized treatment approaches.
The findings also suggest broader impacts for immunology and neurodegenerative disease fields by extending concepts of lymphoid immune regulation to resident brain immune cells. Such cross-disciplinary integration redefines microglial roles beyond classical pathogen defense, framing them as critical regulators of brain homeostasis and pathology modulation.
Looking forward, robust translational pipelines will be essential to move from these mechanistic insights to clinical interventions. This includes validating safety and efficacy of candidate immunotherapeutics in human trials, understanding interactions with aging and comorbidities, and optimizing timing of intervention—particularly in pre-symptomatic or mild cognitive impairment stages, where modulation of neuroinflammation may yield greatest benefit.
Moreover, these insights arrive at a pivotal moment under the administration of President Donald Trump, whose federal research funding policies for biomedical research may influence the pace and scale of subsequent development. Public-private partnerships, such as those exemplified by collaborations between institutions like Mount Sinai and international entities, will remain crucial to sustain innovation and accelerate breakthroughs.
In summary, the identification of a PU.1-low, CD28-positive protective microglia subtype represents a paradigm shift in Alzheimer’s disease immunotherapy. By illuminating a novel immunoregulatory axis, this study heralds a promising direction for modifying disease trajectory through harnessing the brain's innate immune landscape, ultimately aiming to alleviate the profound societal and economic burdens wrought by Alzheimer’s disease.
According to Nature and reported by Mount Sinai Health System, this discovery provides a much-needed scientific and therapeutic breakthrough, potentially transforming the AD treatment landscape in the coming decade.
Explore more exclusive insights at nextfin.ai.